Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT

Bone Marrow Transplantation

Volumn 41, Issue 12, 2008, Pages 1013-1019

  Kumar, S K ^a   Dingli, D ^a   Dispenzieri, A ^a   Lacy, M Q ^a   Hayman, S R ^a   Buadi, F K ^a   Rajkumar, S V ^a   Litzow, M R ^a   Gertz, M A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; THALIDOMIDE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 47849095971     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.24     Document Type: Article

References (32)

1. Jernal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
3. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic, stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
4. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
5. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936.
6. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673-679.
7. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. High-dose therapy and autologous stem cell transplantation for multiple mycloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161-167.
8. Alexanian R, Dimopoulos MA, Delasalle KB, Hester J, Champlin R. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 1995; 13 (Suppl 2): 118-121.
9. Vesole DH, Crowley JJ, Catchatourian R, Stiff PJ, Johnson DB, Cromer J et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: Results of a Southwest Oncology Group phase II trial. J Clin Oncol 1999; 17: 2173-2179.
10. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
11. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/ Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
12. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
13. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
14. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-783.
15. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol, Annual Meeting Abstracts 2007; 25 (Suppl 18): LBA8025.
16. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B et al Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82: 1179-1184.
17. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353-1356.
18. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-3387.
19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
20. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959; 53: 457-481.
21. Cox D. Regression models and life tables. J R Stat Soc 1972; 34 187-202.
22. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, Litzow MR et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384-388.
23. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731-735.
24. Knudsen LM, Rasmussen T, Jensen L, Johnsen HE. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment. Med Oncol 1999; 16: 245-254.
25. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 2004; 34 485-490.
26. Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: 127-130.
27. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887-890.
28. Rajkumar SV, Hussein M, Catalano J, Jedrzejcak W, Sirkovich S, Olesnyckyj M et al. A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma. Am Soc Hematol Annual Meeting Abstracts 2006; 108: 795.
29. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39.
30. Macro M, Divine M, Uzunhan Y, Jaccard A, Bouscary D, Leblond V et al Dexamethasone + thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (mm): A randomized trial. Am Soc Hematol, Annual Meeting Abstracts 2006; 108: 57.
31. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979-983.
32. Harousseau J-L, Attal M, Moreau P, Garban F, Facon T, Avet-Loiseau H. The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma (MM). Combined results of the IFM 99 trials. Am Soc Hematol, Annual Meeting Abstracts 2006; 108: 3077.